Senovia Biosciences is pioneering Metabolic State Medicine — a new therapeutic paradigm that treats disease at its metabolic root. Rather than targeting isolated molecular pathways, Senovia's platform restores defined metabolic states: the physiological equilibrium that healthy cellular function requires. The company's pipeline spans six programs across neurodegeneration, oncology, epilepsy, psychiatry, autism, and metabolic disease — all unified by a single mechanistic platform. Senovia delivers oral, pharmaceutical-grade medicines that achieve controlled, sustained therapeutic metabolic states without dietary intervention.